State Street Corporation has filed a Schedule 13G reporting beneficial ownership of 11,073,211 shares of BioCryst Pharmaceuticals Inc. common stock, representing 5.3% of the class as of the event date.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of 11,073,211 shares of BioCryst Pharmaceuticals Inc. common stock, representing 5.3% of the class as of the event date.
State Street reports no sole voting or dispositive power, with shared voting power over 10,457,690 shares and shared dispositive power over 11,073,211 shares. The holdings are certified as acquired and held in the ordinary course of business, not to change or influence control of BioCryst. Several State Street Global Advisors entities are identified as relevant investment adviser subsidiaries.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in BioCryst Pharmaceuticals (BCRX) does State Street report?
State Street Corporation reports beneficial ownership of 11,073,211 shares of BioCryst Pharmaceuticals common stock, representing 5.3% of the outstanding class. This disclosure reflects its position as a significant institutional holder rather than an insider seeking to influence corporate control.
Does State Street have voting power over its BCRX shares?
State Street reports no sole voting power but shared voting power over 10,457,690 BioCryst shares. It also reports shared dispositive power over 11,073,211 shares, indicating voting and investment decisions are exercised collectively through affiliated entities, not by State Street alone.
Is State Street’s BioCryst (BCRX) position intended to influence control?
State Street certifies the BioCryst shares were acquired and are held in the ordinary course of business, not for changing or influencing control of the issuer. The filing states they are not held in connection with any control-related transaction, except limited nomination-related activities referenced.
Which State Street affiliates are linked to the BioCryst (BCRX) holding?
The filing identifies several investment adviser subsidiaries connected to the holding, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., reflecting a broad asset-management structure.
Why did State Street file a Schedule 13G for BioCryst (BCRX)?
State Street crossed the 5% beneficial ownership threshold in BioCryst common stock, triggering a Schedule 13G institutional investor filing. The 5.3% stake and ordinary-course certification align with passive investment status rather than an activist or control-seeking position in the company.
Who signed the State Street ownership filing for BioCryst (BCRX)?
The statement was signed by Elizabeth Schaefer, identified as Senior Vice President and Chief Accounting Officer. Her signature certifies, after reasonable inquiry, that the information provided about State Street’s beneficial ownership in BioCryst common stock is true, complete, and correct.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
BIOCRYST PHARMACEUTICALS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
09058V103
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
09058V103
1
Names of Reporting Persons
STATE STREET CORPORATION
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,457,690.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
11,073,211.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
11,073,211.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BIOCRYST PHARMACEUTICALS INC
(b)
Address of issuer's principal executive offices:
4505 EMPEROR BLVD SUITE 200, DURHAM, NORTH CAROLINA, 27703
Item 2.
(a)
Name of person filing:
STATE STREET CORPORATION;
(b)
Address or principal business office or, if none, residence:
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)
Citizenship:
MA
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
09058V103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
11073211.00
(b)
Percent of class:
5.3 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
10,457,690
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
11,073,211
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
NOT APPLICABLE
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
NOT APPLICABLE
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
NOT APPLICABLE
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
